Renal Cell Carcinoma (RCC) Prognosis Score

ASSURE RCC Prognosis Calculator

ASSURE RCC Prognosis Calculator

Post-operative calculator for intermediate- and high-risk localized renal cell carcinoma after surgical resection. This version reports separate DFS and OS scores using the published ASSURE point assignments, plus estimated 5-year DFS and OS probabilities.

Age contributes to OS, not DFS.
If papillary subtype cannot be differentiated, classify as the clear-cell/papillary type 2 group.
Published model uses grade 4 vs grade 1–3.
Used for DFS only in the published score table.
DFS Score: 0.0
OS Score: 0.0
Estimated 5-year DFS: —
Estimated 5-year OS: —
Interpretation: —
Higher scores and lower estimated 5-year probabilities indicate worse prognosis.
This calculator is for post-operative prognostic estimation only. It supports follow-up planning and risk communication, but it does not replace oncology judgment or multidisciplinary decision-making.

The RCC Prognosis Score is a post-surgery risk model used to estimate the chance of cancer recurrence and survival in patients with localized renal cell carcinoma after the tumor has been removed. In the ASSURE RCC Prognosis model, it is mainly intended for patients with intermediate- or high-risk localized RCC after surgical resection.

The ASSURE model predicts outcomes such as disease-free survival (DFS) and overall survival (OS). It uses clinicopathologic features from the surgical specimen and patient profile, including factors such as tumor histology, tumor size, grade, necrosis, nodal involvement, and depending on the endpoint, vascular invasion or age.

In simple terms:

  • Lower-risk features suggest a better outlook after surgery
  • Higher-risk features suggest a higher chance of recurrence and lower survival probability over time

Doctors use these scores to help with:

  • follow-up planning
  • counseling about recurrence risk
  • selecting patients for trials or adjuvant-treatment discussions

So, the RCC Prognosis Score is a tool to estimate how likely kidney cancer is to come back and how favorable survival is after surgery; it supports decision-making, but it does not replace oncology judgment.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top